Qiagen (QGEN) Given “Neutral” Rating at DZ Bank

DZ Bank reissued their neutral rating on shares of Qiagen (NASDAQ:QGEN) in a report published on Thursday morning.

Several other analysts have also commented on the stock. TheStreet lowered shares of Qiagen from a b- rating to a c+ rating in a research report on Thursday, February 8th. Zacks Investment Research lowered shares of Qiagen from a hold rating to a sell rating in a research report on Monday, December 11th. Cowen restated a hold rating and set a $34.00 price objective on shares of Qiagen in a report on Thursday, December 21st. Morgan Stanley upped their price objective on shares of Qiagen from $38.00 to $39.00 and gave the company an overweight rating in a report on Friday, February 2nd. Finally, Goldman Sachs assumed coverage on shares of Qiagen in a report on Monday, January 29th. They set a buy rating and a $39.00 price objective on the stock. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Qiagen presently has an average rating of Hold and an average price target of $35.33.

How to Become a New Pot Stock Millionaire

Shares of QGEN stock traded down $0.80 during mid-day trading on Thursday, hitting $31.21. 276,723 shares of the stock traded hands, compared to its average volume of 1,080,128. Qiagen has a 52-week low of $27.74 and a 52-week high of $36.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.07 and a quick ratio of 4.59.

Qiagen (NASDAQ:QGEN) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.43 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.01. The business had revenue of $396.86 million during the quarter, compared to analyst estimates of $394.48 million. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. equities research analysts expect that Qiagen will post 1.34 earnings per share for the current year.

Qiagen declared that its board has initiated a stock buyback plan on Wednesday, January 31st that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Institutional investors and hedge funds have recently bought and sold shares of the company. OxFORD Asset Management LLP increased its holdings in shares of Qiagen by 6.7% during the third quarter. OxFORD Asset Management LLP now owns 81,216 shares of the company’s stock valued at $2,558,000 after acquiring an additional 5,116 shares in the last quarter. AXA increased its holdings in Qiagen by 5.0% in the 3rd quarter. AXA now owns 405,798 shares of the company’s stock worth $12,783,000 after buying an additional 19,268 shares during the period. Citadel Advisors LLC increased its holdings in Qiagen by 816.3% in the 4th quarter. Citadel Advisors LLC now owns 1,051,713 shares of the company’s stock worth $32,529,000 after buying an additional 936,936 shares during the period. Myriad Asset Management Ltd. acquired a new position in Qiagen in the 3rd quarter worth approximately $4,747,000. Finally, Acadian Asset Management LLC increased its holdings in Qiagen by 3.4% in the 4th quarter. Acadian Asset Management LLC now owns 412,888 shares of the company’s stock worth $12,770,000 after buying an additional 13,566 shares during the period. Hedge funds and other institutional investors own 62.23% of the company’s stock.

WARNING: “Qiagen (QGEN) Given “Neutral” Rating at DZ Bank” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3335992/qiagen-qgen-given-neutral-rating-at-dz-bank.html.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Franklin Templeton Investments Sees Unusually Large Options Volume
Franklin Templeton Investments Sees Unusually Large Options Volume
Traders Buy High Volume of Lumber Liquidators Put Options
Traders Buy High Volume of Lumber Liquidators Put Options
Multi-Color  Earns Media Sentiment Rating of 0.33
Multi-Color Earns Media Sentiment Rating of 0.33
Air Transport Services Group  Receives News Impact Rating of 0.15
Air Transport Services Group Receives News Impact Rating of 0.15
Merck & Co.  Upgraded at Morgan Stanley
Merck & Co. Upgraded at Morgan Stanley
MSC Industrial Direct Target of Unusually High Options Trading
MSC Industrial Direct Target of Unusually High Options Trading


Leave a Reply

© 2006-2018 Ticker Report. Google+.